Document:

Exhibit 10.10

 

EMPLOYMENT
AGREEMENT

 

This EMPLOYMENT AGREEMENT
(the “Agreement”) is entered into as of September 14, 2019, by and between CNS Pharmaceuticals, Inc., a Nevada corporation
(the “Company”) having its principal place of business at 2100 West Loop South, Suite 900, Houston, TX 77027,
and Christopher S. Downs (“Executive”, and the Company and the Executive collectively referred to herein as
the “Parties”) having his office at 478 Cynthia Way, North Salt Lake, Utah 84054, or such other location of
his choosing.

 

WITNESSETH:

 

WHEREAS, the Company
desires to hire Executive and to employ him as the Company’s Chief Financial Officer (“CFO”) commencing
on the closing date of the Company’s initial public offering of common stock on the NASDAQ Stock Market (the “Effective
Date”), and the Parties desire to enter into this Agreement embodying the terms of such employment; and

 

NOW, THEREFORE, in
consideration of the premises and the mutual covenants and promises of the Parties contained herein, the Parties, intending to
be legally bound, hereby agree as follows:

 

1.                 
Title and Job Duties.

 

(a)               
Subject to the terms and conditions set forth in this Agreement, commencing on the Effective
Date, the Company agrees to employ Executive as CFO. Executive shall report directly to the Board of Directors of the Company (the
“Board”).

 

(b)              
Executive accepts such employment and agrees, during the term of his employment, to devote
his full business and professional time and energy to the Company, and agrees faithfully to perform his duties and responsibilities
in an efficient, trustworthy and business-like manner. Executive also agrees that the Board shall determine from time to time such
other duties as may be assigned to him. Executive agrees to carry out and abide by such directions of the Board.

 

(c)               
Without limiting the generality of the foregoing, Executive shall not, without the written
approval of the Company, render services of a business or commercial nature on his own behalf or on behalf of any other person,
firm, or corporation, whether for compensation or otherwise, during his employment hereunder. The foregoing limitation shall not
apply to Executive’s involvement in associations, charities and service on another entity’s board of directors, provided
such involvement does not interfere with Executives responsibilities (and as it pertains to any service on another entity’s
board of directors, provided such action is pre-approved by the Company). 

 

2.                 
Salary and Additional Compensation.

 

(a)               
Base Salary. During the Term, the Company shall pay to Executive an annual base salary
(“Base Salary”) of $300,000. The Board shall review the Executive’s Base Salary no less than annually
and may increase (but not decrease) such Base Salary during the term of this Agreement. In addition, on the Effective Date, Executive
shall receive a one-time relocation bonus of $15,000.

 

(b)              
Annual Bonus. For each compensation year during the Term and commencing with the 2019
compensation year (which shall be prorated), Executive will be entitled to receive an annual cash bonus (the “Annual Bonus”),
payable with respect to each compensation year completed during the Term, within ninety (90) days of the completion of such compensation
year. The final determination on the amount, if any, of the Annual Bonus will be made by, and in the sole discretion of the Compensation
Committee (or the Board, if such committee has been dissolved), based on goals and objectives approved by the Compensation Committee
of the Board (or the Board, if such committee has been dissolved). The target Annual Bonus for the 2019 compensation year will
be 35% of Base Salary. The term “compensation year” shall mean the Company’s fiscal year.

 

 

 

    	 	1	 

     

    

 

(c)               
Option Grant. On the Effective Date, Executive will be entitled to receive an option
grant (the “Option Grant”), to purchase 300,000 shares of Company common stock at an exercise price per share
equal to the public offering price per share of the Company’s initial public offering. The Option Grant shall have a term
of ten years and shall vest in four (4) equal installments on each of the succeeding four anniversary dates of the date of grant,
provided Executive remains continuously employed by Company on and does not resign prior to each such vesting date. The Option
Grant shall be made pursuant to the CNS Pharmaceuticals, Inc. 2017 Stock Plan, and shall in all respects be subject to the terms
and conditions of such plan. 

 

3.                 
Expenses. In accordance with Company policy, the Company shall reimburse Executive
for all reasonable association fees, professional related expenses (certifications, licenses and continuing professional education)
and business expenses properly and necessarily incurred and paid by Executive in the performance of his duties under this Agreement,
upon his presentment of detailed receipts in the form required by the Company’s policy. Notwithstanding the foregoing, all
expenses must be promptly submitted for reimbursement by the Executive. In no event shall any reimbursement be paid by the Company
after the end of the year following the year in which the expense is incurred by the Executive. 

 

4.                 
Benefits.

 

(a)               
Vacation. The Executive shall be entitled to reasonable vacation time and to utilize
such vacation as the Executive shall determine; provided however, that the Executive shall evidence reasonable judgment with regard
to appropriate vacation scheduling.

 

(b)              
Health Insurance and Other Plans. Executive shall be eligible to participate in the
Company’s medical, dental and other employee benefit programs, if any, that are provided by the Company for its employees
at Executive’s level in accordance with the provisions of any such plans, as the same may be in effect from time to time.

 

5.                 
Term. The term of employment under this Agreement (the “Term”) shall
be for a three-year period commencing on the Effective Date.

 

6.                 
Termination.

 

(a)               
Termination at the Company’s Election. 

 

(i)                
For Cause. At the election of the Company, Executive’s employment may be terminated
at any time for Cause (as defined below) upon written notice to Executive given pursuant to Section 12 of this Agreement. For purposes
of this Agreement, “Cause” for termination shall mean that Executive: (A) pleads “guilty” or “no
contest” to, or is convicted of an act which is defined as a felony under federal or state law, or is indicted or formally
charged with acts involving criminal fraud or embezzlement; (B) in carrying out his duties, engages in conduct that constitutes
gross negligence or willful misconduct; (C) engages in substantiated fraud, misappropriation or embezzlement against the Company;
(D) engages in any inappropriate or improper conduct that causes material harm to the reputation of the Company; or (E) materially
breaches any term of this Agreement. With respect to subsection (E) of this section, to the extent such material breach may be
cured, the Company shall provide Executive with written notice of the material breach and Executive shall have twenty (20) days
to cure such breach.

 

(ii)              
Upon Disability, Death or Without Cause. At the election of the Company, Executive’s
employment may be terminated: (A) should Executive have a physical or mental impairment that substantially limits a major life
activity and Executive is unable to perform the essential functions of his job with or without reasonable accommodation (“Disability”);
(B) upon Executive’s death; or (C) with ninety (90) days prior written notice, at any time Without Cause for any or no reason.

 

 

 

 

    	 	2	 

     

    

 

(b)              
Termination at Executive’s Election; Good Reason Termination. Notwithstanding
anything contained elsewhere in this Agreement to the contrary, Executive may terminate his employment hereunder at any time and
for any reason, upon thirty (30) days’ prior written notice given pursuant to Section 12 of this Agreement (“Voluntary
Resignation”), provided that upon notice of resignation, the Company may terminate Executive’s employment immediately
and pay Executive thirty (30) days’ Base Salary in lieu of notice. Furthermore, the Executive may terminate this Agreement
for “Good Reason,” which shall be deemed to exist: (i) if the Company’s Board of Directors or that of
any successor entity of Company, fails to appoint or reappoint the Executive or removes the Executive as the CFO of the Company;
or (ii) a material breach by the Company of this Agreement. Good Reason shall not exist hereunder unless the Executive provides
notice in writing to the Company of the existence of a condition described above within a period not to exceed ninety (90) days
of the initial existence of the condition, and with respect to subsection (ii) of this section, to the extent such material breach
may be cured, the Company does not remedy the condition within thirty (30) days of receipt of such notice.

 

(c)               
Termination in General. If Executive’s employment with the Company terminates
for any reason, the Company will pay or provide to Executive: (i) any unpaid Salary through the date of employment termination,
(ii) reimbursement for any unreimbursed business expenses incurred through the termination date, to the extent reimbursable in
accordance with Section 3, and (iii) all other payments or benefits (if any) to which Executive is entitled under the terms of
any benefit plan or arrangement. 

 

7.                 
Severance.

 

(a)               
Subject to Section 7(b) below, if Executive’s employment is terminated prior to the
end of the Term, either by the Company without Cause or by Executive for Good Reason, Executive shall be entitled to receive a
severance payment equal to six (6) months of Executive’s Base Salary. Such severance payment shall be made in a single lump
sum sixty (60) days following such termination, provided the Executive has executed and delivered to the Company, and has not revoked
a general release of the Company, its parents, subsidiaries and affiliates and each of its officers, directors, employees, agents,
successors and assigns, and such other persons and/or entities as the Company may determine, in a form reasonably acceptable to
the Company. Such general release shall be delivered on or about the date of termination and must be executed within fifty-five
(55) days of termination.

 

(b)              
Notwithstanding the foregoing, (i) any payment(s) of “nonqualified deferred compensation”
(within the meaning of Section 409A of the Code and the regulations and official guidance issued thereunder (“Section 409A”))
that is/are required to be made to Executive hereunder as a “specified employee” (as defined under Section 409A) as
a result of such employee’s “separation from service” (within the meaning of Section 409A) shall be delayed for
the first six (6) months following such separation from service (or, if earlier, the date of death of the specified employee) and
shall instead be paid upon expiration of such six (6) month delay period; and (ii) for purposes of any such payment that is subject
to Section 409A, if the Executive’s termination of employment triggers the payment of “nonqualified deferred compensation”
hereunder, then the Executive will not be deemed to have terminated employment until the Executive incurs a “separation from
service” within the meaning of Section 409A.

 

8.                 
Confidentiality Agreement.

 

(a)               
Executive understands that during the Term he may have access to unpublished and otherwise
confidential information both of a technical and non-technical nature, relating to the business of the Company and any of its parents,
subsidiaries, divisions, affiliates (collectively, “Affiliated Entities”), or clients, including without limitation
any of their actual or anticipated business, research or development, any of their technology or the implementation or exploitation
thereof, including without limitation information Executive and others have collected, obtained or created, information pertaining
to patent formulations, vendors, prices, costs, materials, processes, codes, material results, technology, system designs, system
specifications, materials of construction, trade secrets and equipment designs, including information disclosed to the Company
by others under agreements to hold such information confidential (collectively, the “Confidential Information”).
Executive agrees to observe all Company policies and procedures concerning such Confidential Information. Executive further agrees
not to disclose or use, either during his employment or at any time thereafter, any Confidential Information for any purpose, including
without limitation any competitive purpose, unless authorized to do so by the Company in writing, except that he may disclose and
use such information when necessary in the performance of his duties for the Company. Executive’s obligations under this
Agreement will continue with respect to Confidential Information, whether or not his employment is terminated, until such information
becomes generally available from public sources through no action of Executive. Notwithstanding the foregoing, however, Executive
shall be permitted to disclose Confidential Information as may be required by a subpoena or other governmental order, provided
that he first notifies promptly the Company of such subpoena, order or other requirement and allows the Company the opportunity
to obtain a protective order or other appropriate remedy.

 

 

 

 

    	 	3	 

     

    

 

(b)              
During Executive’s employment, upon the Company’s request, or upon the termination
of his employment for any reason, Executive will promptly deliver to the Company all documents, records, files, notebooks, manuals,
letters, notes, reports, customer and supplier lists, cost and profit data, e-mail, apparatus, computers, cell phones, tablets,
hardware, software, drawings, and any other material of the Company or any of its Affiliated Entities or clients, including all
materials pertaining to Confidential Information developed by Executive or others, and all copies of such materials, whether of
a technical, business or fiscal nature, whether on the hard drive of a laptop or desktop computer, in hard copy, disk or any other
format, which are in Executive’s possession, custody or control.

 

(c)               
Executive will promptly disclose to the Company any idea, invention, discovery or improvement,
whether patentable or not (“Creations”), conceived or made by him alone or with others at any time during his
employment. Executive agrees that the Company owns all such Creations, conceived or made by Executive alone or with others at any
time during his employment, and Executive hereby assigns and agrees to assign to the Company all rights he has or may acquire therein
and agrees to execute any and all applications, assignments and other instruments relating thereto which the Company deems necessary
or desirable. These obligations shall continue beyond the termination of his employment with respect to Creations and derivatives
of such Creations conceived or made during his employment with the Company. Executive understands that the obligation to assign
Creations to the Company shall not apply to any Creation which is developed entirely on his own time without using any of the Company’s
equipment, supplies, facilities, and/or Confidential Information unless such Creation (a) relates in any way to the business
or to the current or anticipated research or development of the Company or any of its Affiliated Entities; or (b) results
in any way from his work at the Company.

 

(d)              
Executive will not assert any rights to any invention, discovery, idea or improvement relating
to the business of the Company or any of its Affiliated Entities or to his duties hereunder as having been made or acquired by
Executive prior to his work for the Company, except for the matters, if any, described in Appendix A to this Agreement.

 

(e)               
During the Term, if Executive incorporates into a product or process of the Company or any
of its Affiliated Entities anything listed or described in Appendix A, the Company is hereby granted and shall have
a non-exclusive, royalty-free, irrevocable, perpetual, worldwide license (with the right to grant and authorize sublicenses) to
make, have made, modify, use, sell, offer to sell, import, reproduce, distribute, publish, prepare derivative works of, display,
perform publicly and by means of digital audio transmission and otherwise exploit as part of or in connection with any product,
process or machine.

 

(f)               
Executive agrees to cooperate fully with the Company, both during and after his employment
with the Company, with respect to the procurement, maintenance and enforcement of copyrights, patents, trademarks and other intellectual
property rights (both in the United States and foreign countries) relating to such Creations. Executive shall sign all papers,
including, without limitation, copyright applications, patent applications, declarations, oaths, formal assignments, assignments
of priority rights and powers of attorney, which the Company may deem necessary or desirable in order to protect its rights and
interests in any Creations. Executive further agrees that if the Company is unable, after reasonable effort, to secure Executive’s
signature on any such papers, any officer of the Company shall be entitled to execute such papers as his agent and attorney-in-fact
and Executive hereby irrevocably designates and appoints each officer of the Company as his agent and attorney-in-fact to execute
any such papers on his behalf and to take any and all actions as the Company may deem necessary or desirable in order to protect
its rights and interests in any Creations, under the conditions described in this paragraph.

 

 

 

 

    	 	4	 

     

    

 

9.                 
Non-solicitation; non-competition. (a) Executive agrees that, during the Term and until
six (6) months after the termination of his employment, Executive will not, directly or indirectly, including on behalf of any
person, firm or other entity, employ or actively solicit for employment any employee of the Company or any of its Affiliated Entities,
or anyone who was an employee of the Company or any of its Affiliated Entities within the one-year period prior to the termination
of Executive’s employment, or induce any such employee to terminate his or her employment with the Company or any of its
Affiliated Entities.

 

(b)       Executive
further agrees that, during the Term and until six (6) months after the termination of his employment, Executive will not, directly
or indirectly, including on behalf of any person, firm or other entity, without the express written consent of an authorized representative
of the Company, (i) perform services within the Territory (as defined below) for any Competing Business (as defined below), whether
as an employee, consultant, agent, contractor or in any other capacity, (ii) hold office as an officer or director or like position
in any Competing Business (unless Executive is already serving as a director of such company at the time of termination of his
employment), or (iii) request any present or future customers or suppliers of the Company or any of its Affiliated Entities to
curtail or cancel their business with the Company or any of its Affiliated Entities. These obligations will continue for the specified
period regardless of whether the termination of Executive’s employment was voluntary or involuntary or with or without Cause
or for any other reason.

 

(c)       “Competing
Business” means any corporation, partnership or other entity or person (other than the Company) which is engaged (a)
in the development, manufacture, marketing, distribution or sale of, or research directed to the development, manufacture, marketing,
distribution or sale of competing anti-cancer drug candidates or products or (b) in any other business activity carried on or planned
to be carried on (as evidenced by existing written documentation) by the Company or any of its Affiliated Entities during the Term.

 

(d)       “Territory”
shall mean within any state, country or foreign jurisdiction in which the Company or any subsidiary of the Company is then providing
services or products or marketing its services or products (or engaged in active discussions to provide such services).

 

(e)        Executive
agrees that in the event a court determines the length of time or the geographic area or activities prohibited under this Section
9 are too restrictive to be enforceable, the court shall reduce the scope of the restriction to the extent necessary to make the
restriction enforceable. In furtherance and not in limitation of the foregoing, the Company and the Executive each intend that
the covenants contained in this Section 9 shall be deemed to be a series of separate covenants, one for each and every state, territory
or jurisdiction of the United States and any foreign country set forth therein.  If, in any judicial proceeding, a court shall
refuse to enforce any of such separate covenants, then such unenforceable covenants shall be deemed eliminated from the provisions
hereof for the purpose of such proceedings to the extent necessary to permit the remaining separate covenants to be enforced in
such proceedings.

 

10.             
Representation and Warranty. The Executive hereby acknowledges and represents that
he has had the opportunity to consult with legal counsel regarding his rights and obligations under this Agreement and that he
fully understands the terms and conditions contained herein. Executive represents and warrants that Executive has provided the
Company a true and correct copy of any agreements that purport: (a) to limit Executive’s right to be employed by the Company;
(b) to prohibit Executive from engaging in any activities on behalf of the Company; or (c) to restrict Executive’s right
to use or disclose any information while employed by the Company. Executive further represents and warrants that Executive will
not use on the Company’s behalf any information, materials, data or documents belonging to a third party that are not generally
available to the public, unless Executive has obtained written authorization to do so from the third party and provided such authorization
to the Company. In the course of Executive’s employment with the Company, Executive is not to breach any obligation of confidentiality
that Executive has with third parties, and Executive agrees to fulfill all such obligations during Executive’s employment
with the Company. Executive further agrees not to disclose to the Company or use while working for the Company any trade secrets
belonging to a third party. 

 

11.             
Injunctive Relief. Without limiting the remedies available to the Company, Executive
acknowledges that a breach of any of the covenants contained in Sections 8 and 9 above may result in material irreparable injury
to the Company for which there is no adequate remedy at law, that it will not be possible to measure precisely damages for such
injuries and that, in the event of such a breach or threat thereof, the Company shall be entitled, without the requirement to post
bond or other security, to seek a temporary restraining order and/or injunction restraining Executive from engaging in activities
prohibited by this Agreement or such other relief as may be required to specifically enforce any of the covenants in Sections 8
and 9 of this Agreement.

 

 

 

 

    	 	5	 

     

    

 

12.             
Notice. Any notice or other communication required or permitted to be given to the
Parties shall be deemed to have been given if either personally delivered, or if sent for next-day delivery by nationally recognized
overnight courier, and addressed as follows:

 

If to Executive, to:

 

Christopher S. Downs

478 Cynthia Way

North Salt Lake, Utah 84054

 

 

If to the Company, to:

 

CNS Pharmaceuticals, Inc.

2100 West Loop South, Suite 900

Houston, TX 77027

Attention: CEO

 

13.             
Severability. If any provision of this Agreement is declared void or unenforceable
by a court of competent jurisdiction, all other provisions shall nonetheless remain in full force and effect.

 

14.             
Withholding.  The Company may withhold from any payment that it is required to
make under this Agreement amounts sufficient to satisfy applicable withholding requirements under any federal, state or local law.

 

15.             
Indemnification. The Company agrees that Executive will be covered by any “directors
and officers” insurance policies then in effect with respect to Executive’s acts as an officer and/or director of the
Company.

 

16.             
Governing Law. This Agreement shall be governed by, and construed and enforced in accordance
with, the laws of the State of Nevada, without regard to the conflict of laws provisions thereof. Any action, suit or other legal
proceeding that is commenced to resolve any matter arising under or relating to any provision of this Agreement shall be submitted
to the exclusive jurisdiction of any state or federal court in Las Vegas, Nevada.

 

17.             
Waiver. The waiver by either Party of a breach of any provision of this Agreement shall
not be or be construed as a waiver of any subsequent breach. The failure of a Party to insist upon strict adherence to any provision
of this Agreement on one or more occasions shall not be considered a waiver or deprive that Party of the right thereafter to insist
upon strict adherence to that provision or any other provision of this Agreement. Any such waiver must be in writing, signed by
the Party against whom such waiver is to be enforced.

 

18.             
Assignment. This Agreement is a personal contract and Executive may not sell, transfer,
assign, pledge or hypothecate his rights, interests and obligations hereunder. Except as otherwise herein expressly provided, this
Agreement shall be binding upon and shall inure to the benefit of Executive and his personal representatives and shall inure to
the benefit of and be binding upon the Company and its successors and assigns, including without limitation, any corporation or
other entity into which the Company is merged or which acquires all or substantially all of the assets of the Company.

 

19.             
Entire Agreement. This Agreement (together with Appendix A hereto) embodies
all of the representations, warranties, covenants, understandings and agreements between the Parties relating to Executive’s
employment with the Company. No other representations, warranties, covenants, understandings, or agreements exist between the Parties
relating to Executive’s employment. This Agreement shall supersede all prior agreements, written or oral, relating to Executive’s
employment. This Agreement may not be amended or modified except by a writing signed by the Parties.

 

[Signature page follows]

 

 

    	 	6	 

     

    

 

IN WITNESS WHEREOF,
the Parties have caused this Agreement to be duly executed and delivered on the date first written above.

 

	 	CNS Pharmaceuticals, Inc. 
	 	 
	 	 
	 	 
	 	By:	
        /s/ John Climaco

	 	
        Name: John Climaco

        Title: CEO

	
         

         

        Agreed to and Accepted:
	 
	Christopher S. Downs	 
	
         

         

         
	 
	
        /s/ Christopher S. Downs
	 
	 	 
	Date: 9/14/2019	 

 

 

 

 

 

 

    	 	7	 

     

    

 

Appendix A

 

None.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	8EX-4.2

 Exhibit 4.2 

Execution Version 
  

 
 THERMO FISHER SCIENTIFIC INC., 

as Issuer 
 AND 

THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., 

as Trustee 
 NINETEENTH
SUPPLEMENTAL INDENTURE 
 Dated as of October 8, 2019 

2.600% Senior Notes due 2029 

 THIS NINETEENTH SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”) is
dated as of October 8, 2019 between THERMO FISHER SCIENTIFIC INC., a Delaware corporation (the “Company”), and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., a national banking association, as trustee (the
“Trustee”). 
 RECITALS 

WHEREAS, the Company and the Trustee executed and delivered an Indenture, dated as of November 20, 2009 (the “Base
Indenture” and, as supplemented by this Supplemental Indenture, the “Indenture”), to provide for the issuance by the Company from time to time of unsubordinated debt securities evidencing its unsecured indebtedness. 

WHEREAS, the Company has authorized the issuance of $900,000,000 aggregate principal amount of the Company’s 2.600% Senior Notes due 2029
(the “Notes”). 
 WHEREAS, the entry into this Supplemental Indenture by the parties hereto is in all respects authorized
by the provisions of the Base Indenture. 
 WHEREAS, the Company desires to enter into this Supplemental Indenture pursuant to
Section 9.01 of the Base Indenture to establish the terms of the Notes in accordance with Section 2.01 of the Base Indenture and to establish the form of the Notes in accordance with Sections 2.01(a)(10) and 2.02 of the Base
Indenture. 
 WHEREAS, all things necessary to make this Supplemental Indenture a valid and legally binding agreement according to its terms
have been done. 
 NOW, THEREFORE, for and in consideration of the foregoing premises, the Company and the Trustee, mutually covenant and
agree for the equal and proportionate benefit of the respective Holders from time to time of the Notes as follows: 
 ARTICLE I 

Section 1.1 Defined Terms. 
 (1)
Capitalized terms used but not defined in this Supplemental Indenture shall have the meanings ascribed thereto in the Base Indenture. 
 (2)
A term defined anywhere in this Supplemental Indenture has the same meaning throughout. 
 (3) The singular includes the plural and vice
versa. 
 (4) Headings are for convenience of reference only and do not affect the interpretation. 

  
 1 

 (5) As used herein, the following defined terms shall have the following meanings with
respect to the Notes and this Supplemental Indenture only: 
 “Below Investment Grade Rating Event” means the Notes are
downgraded below an Investment Grade Rating by any two of the Rating Agencies on any date during the period (the “Trigger Period”) commencing 60 days prior to the first public announcement by the Company of the occurrence of a
Change of Control (or pending Change of Control) and ending 60 days following consummation of such Change of Control (which Trigger Period shall be extended so long as the rating of the Notes is under publicly announced consideration for possible
downgrade by at least two of such Rating Agencies on such 60th day, such extension to last with respect to each such Rating Agency until the date on which such Rating Agency considering such possible downgrade either (x) rates the Notes below
an Investment Grade Rating or (y) publicly announces that it is no longer considering the Notes for possible downgrade, provided that no such extension will occur if on such 60th day the Notes have an Investment Grade Rating from at least two
of such Rating Agencies in question and are not subject to review for possible downgrade by such Rating Agencies). 
 “Business
Day” means any day, other than a Saturday or Sunday or a day on which Federal or State banking institutions in the Borough of Manhattan, The City of New York are authorized or required by law, regulation or executive order to close. 

“Change of Control” means the occurrence of any of the following: (1) the direct or indirect sale, transfer, conveyance
or other disposition (other than by way of merger or consolidation), in one or a series of related transactions, of all or substantially all of the properties or assets of the Company and its subsidiaries taken as a whole to any “person”
(as that term is used in Section 13(d)(3) of the Exchange Act) other than the Company or one of its direct or indirect wholly-owned subsidiaries; (2) the consummation of any transaction (including, without limitation, any merger or
consolidation) as a result of which any “person” (as that term is used in Section 13(d)(3) of the Exchange Act) becomes the “beneficial owner” (as defined in Rules 13d-3 and 13d-5 under the Exchange Act), directly or indirectly, of more than 50% of the Company’s outstanding Voting Stock or other Voting Stock into which the Company’s Voting Stock is reclassified, consolidated,
exchanged or changed, measured by voting power rather than number of shares; (3) the Company consolidates with, or merges with or into, any “person” or “group” (as that term is used in Section 13(d)(3) of the Exchange
Act), or any “person” or “group” consolidates with, or merges with or into, the Company, in any such event pursuant to a transaction in which any of the Company’s Voting Stock or the Voting Stock of such other person is
converted into or exchanged for cash, securities or other property, other than any such transaction where the shares of the Company’s Voting Stock outstanding immediately prior to such transaction constitute, or are converted into or exchanged
for, a majority of the Voting Stock of the surviving person or any direct or indirect parent company of the surviving person immediately after giving effect to such transaction; or (4) the adoption of a plan relating to the Company’s
liquidation or dissolution. 
 Notwithstanding the foregoing, a transaction will not be deemed to involve a Change of Control if
(a) the Company becomes a direct or indirect wholly-owned subsidiary of a holding company (which shall include a parent company) and (b)(i) the holders of the Voting Stock of such holding company immediately following that transaction are
substantially the same as the holders of the Voting Stock of the Company immediately prior to that transaction or (ii) no “person” (as that term is used in Section 13(d)(3) of the Exchange Act) (other than a holding company
satisfying the requirements of this sentence) becomes the “beneficial owner” (as defined in Rules 13d-3 and 13d-5 under the Exchange Act), directly or
indirectly, of more than 50% of the voting power of the Voting Stock of such holding company immediately following such transaction. 

  
 2 

 “Change of Control Triggering Event” means the occurrence of both a Change
of Control and a Below Investment Grade Rating Event. 
 “Comparable Treasury Issue” means the U.S. Treasury security
selected by the Independent Investment Banker as having an actual or interpolated maturity comparable to the remaining term of the Notes to be redeemed (assuming that such Notes to be redeemed matured on the Par Call Date) that would be utilized, at
the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term of the Notes to be redeemed. 

“Comparable Treasury Price” means, with respect to any Optional Redemption Date, (a) the average of the Reference
Treasury Dealer Quotations for such Optional Redemption Date, after excluding the highest and lowest of the Reference Treasury Dealer Quotations, (b) if the Company obtains fewer than four Reference Treasury Dealer Quotations, the arithmetic
average of those quotations or (c) if the Company obtains only one Reference Treasury Dealer Quotation, such Reference Treasury Dealer Quotation. 

“Fitch” means Fitch Ratings, Limited, and any successor to its rating agency business. 

“Independent Investment Banker” means any Reference Treasury Dealer appointed by the Company as Independent Investment Banker
(initially, BofA Securities, Inc.). 
 “Investment Grade Rating” means a rating by Moody’s equal to or higher than
Baa3 (or the equivalent under a successor rating category of Moody’s) or a rating by S&P equal to or higher than BBB- (or the equivalent under any successor rating category of S&P) or a rating by
Fitch equal to or higher than BBB- (or the equivalent under any successor rating category of Fitch). 

“Moody’s” means Moody’s Investors Service, Inc., and any successor to its rating agency business. 

“Optional Redemption Date” when used with respect to any Note to be redeemed at the Company’s option, means the date
fixed for such redemption by or pursuant to Section 1.3 of this Supplemental Indenture. 
 “Optional Redemption Price”
when used with respect to any Note to be redeemed at the Company’s option, means the price at which it is to be redeemed pursuant to Section 1.3 of this Supplemental Indenture. 

“Par Call Date” means July 1, 2029. 

  
 3 

 “Rating Agencies” means (1) Moody’s, S&P and Fitch; and
(2) if any of Moody’s, S&P or Fitch ceases to rate the Notes or fails to make a rating of the Notes publicly available for any reason, a “nationally recognized statistical rating organization” within the meaning of
Section 3(a)(62) of the Exchange Act, selected by the Company (as certified by a resolution of its Board of Directors) as a replacement agency for any of Moody’s, S&P or Fitch, or all of them, as the case may be. 

“Reference Treasury Dealer” means each of (i) BofA Securities, Inc., Goldman Sachs & Co. LLC, Credit Suisse
Securities (USA) LLC and HSBC Securities (USA) Inc. and their respective affiliates or successors and (ii) one other nationally recognized investment banking firm (or its affiliate) that the Company selects in connection with the particular
redemption, and its successors, provided that if at any time any of the above is not a primary U.S. Government securities dealer, the Company will substitute that entity with another nationally recognized investment banking firm that the Company
selects that is a primary U.S. Government securities dealer. 
 “Reference Treasury Dealer Quotations” means, with respect
to each Reference Treasury Dealer and any Optional Redemption Date, the arithmetic average, as determined by the Independent Investment Banker, of the bid and asked prices for the Comparable Treasury Issue (expressed, in each case, as a percentage
of its principal amount) quoted in writing to the Independent Investment Banker by such Reference Treasury Dealer at 3:30 p.m., New York City time, on the third Business Day preceding such Optional Redemption Date. 

“Remaining Scheduled Payments” means, with respect to each Note to be redeemed, the remaining scheduled payments of the
principal thereof and interest thereon that would be due after the related Optional Redemption Date but for such redemption (assuming that such Notes to be redeemed matured on the Par Call Date); provided, however, that, if such Optional
Redemption Date is not an interest payment date with respect to the Notes, the amount of the next succeeding scheduled interest payment thereon will be reduced by the amount of interest accrued thereon to such Optional Redemption Date. 

“S&P” means S&P Global Ratings, a division of S&P Global, Inc., and any successor to its rating agency business.

 “Treasury Rate” means, for any Optional Redemption Date, the rate per annum equal to the semi-annual equivalent yield to
maturity or interpolated yield to maturity, computed as the second Business Day immediately preceding that Optional Redemption Date, of the Comparable Treasury Issue, assuming a price for the Comparable Treasury Issue (expressed as a percentage of
its principal amount) equal to the Comparable Treasury Price for that Optional Redemption Date. 
 Section 1.2 Terms of the Notes. 

The following terms relate to the Notes: 

(1) The Notes shall constitute a separate series of Notes having the title “2.600% Senior Notes due 2029”. 

  
 4 

 (2) The aggregate principal amount of the Notes (the “Initial Notes”) that
may be initially authenticated and delivered under the Indenture shall be $900,000,000. The Company may from time to time, without the consent of the Holders, issue additional Notes (in any such case, “Additional Notes”) having the
same terms (except for the issue date, offering price and, if applicable, the first interest payment date) as the Initial Notes. Any Additional Notes and the Initial Notes shall constitute a single series under the Indenture; provided that if any
Additional Notes are not fungible with the Initial Notes for U.S. federal income tax purposes, such Additional Notes shall not have the same CUSIP or ISIN numbers as the Initial Notes. All references to the Notes shall include both the Initial Notes
and any Additional Notes, unless the context otherwise requires. The aggregate principal amount of the Notes shall be unlimited. 
 (3) The
entire Outstanding principal amount of the Notes shall be payable on October 1, 2029. 
 (4) The rate at which the Notes shall bear
interest shall be 2.600% per annum. The date from which interest shall accrue on the Notes shall be the most recent Interest Payment Date to which interest has been paid or provided for or, if no interest has been paid, from October 8, 2019.
The Interest Payment Dates for the Notes shall be April 1 and October 1 of each year, beginning on April 1, 2020, until the principal is paid or made available for payment. Interest shall be payable in arrears on each Interest Payment
Date to the holders of record at the close of business on the March 17 and September 16 prior to each such Interest Payment Date (each, a “regular record date”). The basis upon which interest shall be calculated for the
Notes shall be that of a 360-day year consisting of twelve 30-day months. 

(5) The Notes shall be issuable in whole in the form of one or more registered Global Securities, and the Depository for such Global Securities
shall be The Depository Trust Company, New York, New York. The Notes shall be substantially in the form attached hereto as Exhibit A, the terms of which are herein incorporated by reference. The Notes shall be issuable in denominations of $2,000 or
any integral multiple of $1,000 in excess thereof. 
 (6) The Notes may be redeemed at the option of the Company prior to the maturity date,
as provided in Section 1.3 hereof. 
 (7) The Notes shall not have the benefit of any sinking fund. 

(8) Except as provided herein, the Holders shall have no special rights in addition to those provided in the Base Indenture upon the occurrence
of any particular events. 
 (9) The Notes shall be general unsecured and unsubordinated obligations of the Company and shall be ranked
equally among themselves. 
 (10) The Notes are not convertible into shares of common stock or other securities of the Company. 

(11) The covenants set forth in Section 1.4 hereof shall be applicable to the Notes. 

(12) The transfer and exchange provisions set forth in Section 2.05 of the Base Indenture shall be applicable to the Notes. 

  
 5 

 Section 1.3 Optional Redemption. 

(a) The provisions of Article III of the Base Indenture, as amended by the provisions of this Supplemental Indenture, shall apply to the Notes
with respect to this Section 1.3. 
 (b) Prior to the Par Call Date, the Notes shall be redeemable, in whole at any time or in part from
time to time, at the Company’s option. Upon redemption of the Notes, the Company shall pay an Optional Redemption Price equal to the greater of: 
  

	 	(i)	 100% of the principal amount of the Notes to be redeemed, and 

 

	 	(ii)	 the sum of the present values of the Remaining Scheduled Payments of the Notes to be redeemed, discounted to
the Optional Redemption Date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) using a discount rate equal to the Treasury Rate, plus
15 basis points; 

 plus, in each case, in addition to such Optional Redemption Price, accrued and unpaid interest thereon, if any,
to, but excluding, the Optional Redemption Date. 
 On and after the Par Call Date, the Notes shall be redeemable, in whole at any time or
in part from time to time, at the Company’s option, at an Optional Redemption Price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the Optional Redemption Date.

 The Company shall calculate the Optional Redemption Price. 

(c) Notwithstanding the foregoing, installments of interest whose Stated Maturity is on or prior to any Optional Redemption Date shall be
payable on the applicable Interest Payment Date to the Holders of the Notes registered as such at the close of business on the applicable regular record date pursuant to the Notes and the Indenture. 

(d) On and after the Optional Redemption Date for the Notes, interest shall cease to accrue on the Notes or any portion thereof called for
redemption, unless the Company defaults in the payment of the Optional Redemption Price and accrued and unpaid interest, if any. On or before the Business Day prior to the Optional Redemption Date for the Notes to be redeemed, the Company shall
deposit with the Trustee or a paying agent, funds sufficient to pay the Optional Redemption Price of the Notes on the Optional Redemption Date, and (except if the date fixed for redemption shall be an Interest Payment Date) accrued and unpaid
interest, if any. If less than all of the Notes are to be redeemed, the Notes to be redeemed shall be selected, in the case of global securities, in accordance with applicable Depositary procedures and, in the case of definitive securities, in a
manner the trustee deems fair and appropriate, unless otherwise required by law or applicable stock exchange requirements. 
 (e) Notice of
any optional redemption shall be transmitted at least 15 days but not more than 60 days before the Optional Redemption Date to each Holder of the Notes to be redeemed; provided, however, that the Company shall notify the Trustee of the
Optional Redemption Date at least 15 days prior to the date of the giving of such notice (unless a shorter 

  
 6 

 
notice shall be satisfactory to the Trustee). Any notice may, at the Company’s discretion, be subject to the satisfaction or waiver of one or more conditions precedent. In that case, the
notice shall state the nature of such condition precedent. Such notice shall be provided in accordance with Section 3.02 of the Base Indenture. If the Optional Redemption Price cannot be determined at the time such notice is to be given, the
actual Optional Redemption Price, calculated as described above in clause (b), shall be set forth in an Officers’ Certificate of the Company delivered to the Trustee no later than two (2) Business Days prior to the Optional Redemption
Date. Notice of redemption having been given as provided in the Indenture, the Notes called for redemption shall (subject to the satisfaction or waiver of any applicable condition precedent), on the Optional Redemption Date, become due and payable
at the Optional Redemption Price, plus accrued and unpaid interest, if any, to, but excluding, the Optional Redemption Date. 
 Section 1.4
Additional Covenant. 
 The following additional covenant shall apply with respect to the Notes so long as any of the Notes remain
Outstanding: 
 (a) If a Change of Control Triggering Event occurs, unless the Company shall have redeemed the Notes in full, as set forth in
Section 1.3 of this Supplemental Indenture or the Company shall have defeased the Notes or have satisfied and discharged the Notes, as set forth in Article XI of the Base Indenture, the Company shall make an offer (the “Change of
Control Offer”) to each Holder of the Notes to repurchase any and all of such Holder’s Notes at a repurchase price in cash equal to 101% of the aggregate principal amount of the Notes to be repurchased (such principal amount to be
equal to $2,000 or an integral multiple of $1,000 in excess thereof), plus accrued and unpaid interest, if any, on the Notes to be repurchased up to, but excluding, the date of repurchase (the “Change of Control Payment”). Within 30
days following any Change of Control Triggering Event, notice shall be delivered to the Holders of Notes describing the transaction or transactions that constitute the Change of Control Triggering Event and offering to repurchase the Notes on the
date specified in the notice, which date will be no earlier than 15 days and no later than 60 days from the date such notice is delivered (the “Change of Control Payment Date”). Notwithstanding the foregoing, installments of
interest whose Stated Maturity is on or prior to the Change of Control Payment Date shall be payable on the applicable Interest Payment Date to the Holders of the Notes registered as such at the close of business on the applicable regular record
date pursuant to the Notes and the Indenture. 
 (b) On the Change of Control Payment Date, the Company shall, to the extent lawful: 

 

	 	(i)	 accept for payment all Notes or portions of Notes properly tendered pursuant to the Change of Control Offer;

  

	 	(ii)	 deposit with the Trustee or a paying agent an amount equal to the Change of Control Payment in respect of all
Notes or portions of Notes properly tendered; and 

  

	 	(iii)	 deliver or cause to be delivered to the Trustee the Notes properly accepted, together with an Officer’s
Certificate stating (1) the aggregate principal amount of Notes or portions of Notes being repurchased (2) that all conditions precedent contained herein to make a Change of Control Offer have been complied with and (3) that the
Change of Control Offer has been made in compliance with the Indenture. 

  
 7 

 The Company shall comply in all material respects with the requirements of Rule 14e-1 under the Exchange Act and any other securities laws and regulations thereunder to the extent such laws and regulations are applicable in connection with the repurchase of the Notes as a result of a
Change of Control Triggering Event. To the extent that the provisions of any such securities laws or regulations conflict with this Section 1.4, the Company shall comply with the applicable securities laws and regulations and shall not be
deemed to have breached its obligations under this Section 1.4 by virtue of any such conflict. 
 Section 1.5 Events of Default. 

(a) The provisions of Article VI of the Base Indenture shall be applicable to the Notes, except that clauses (1) through (7) of
Section 6.01 (a) shall be modified with respect to the Notes as follows: 
 (1) default in the payment of the principal
or any premium on the Notes when due (whether at maturity, upon acceleration, redemption or otherwise); 
 (2) default for 30
days in the payment of interest on the Notes when due; 
 (3) (i) failure by the Company to comply with Section 1.4 of
this Supplemental Indenture or (ii) failure by the Company to observe or perform any term of the Indenture (other than those referred to in (1) or (2) above or (3)(i) above) for a period of 90 days after the Company receives a notice of
default stating that the Company is in breach. The notice required under 3(ii) above must be sent by either the Trustee or Holders of 25% of the principal amount of the Notes; 

(4) (A) failure by the Company to pay indebtedness for money borrowed by the Company or for which the Company has guaranteed
the payment, in an aggregate principal amount of at least $150,000,000, at the later of final maturity and the expiration of any related applicable grace period and such defaulted payment shall not have been made, waived or extended within 30 days
or (B) acceleration of the maturity of any indebtedness for money borrowed by the Company or for which the Company has guaranteed the payment, in an aggregate principal amount of at least $150,000,000, if such indebtedness has not been
discharged in full or such acceleration has not been rescinded or annulled within 30 days; provided, however, that, if the default under the instrument is cured by the Company, or waived by the holders of the indebtedness, in each case as
permitted by the governing instrument, then the Event of Default under the Indenture caused by such default will be deemed likewise to be cured or waived; 

(5) the entry by a court having competent jurisdiction of: 

(A) an order for relief in respect of the Company as debtor in an involuntary proceeding under any applicable Bankruptcy Law
and such order shall remain unstayed and in effect for a period of 60 consecutive days; or 

  
 8 

 (B) a final and non-appealable order
appointing a Custodian of the Company, or ordering the winding up or liquidation of the affairs of the Company, and such order shall remain unstayed and in effect for a period of 60 consecutive days; or 

(6) the commencement by the Company of a voluntary proceeding under any applicable Bankruptcy Law or the consent by the Company
as debtor to the entry of a decree or order for relief in an involuntary proceeding under any applicable Bankruptcy Law, or the filing by the Company as debtor of a consent to an order for relief in any involuntary proceeding under any Bankruptcy
Law, or to the appointment of a Custodian or the making by the Company of an assignment for the benefit of creditors. 
 ARTICLE II 

MISCELLANEOUS 
 Section 2.1 Business
Day. 
 If any Interest Payment Date, maturity date or earlier date of redemption falls on a day that is not a Business Day, the required
payment shall be made on the next Business Day as if it were made on the date the payment to Holders was due and no interest shall accrue on the amount so payable for the period from and after that Interest Payment Date, that maturity date or that
date of redemption, as the case may be. 
 Section 2.2 [Reserved]. 

Section 2.3 Confirmation of Indenture. 

The Base Indenture, as supplemented and amended by this Supplemental Indenture, is in all respects ratified and confirmed, and the Base
Indenture, this Supplemental Indenture and all indentures supplemental thereto shall be read, taken and construed as one and the same instrument. 

Section 2.4 Concerning the Trustee. 

In carrying out its responsibilities hereunder, the Trustee shall have all of the rights, protections and immunities which it possesses under
the Indenture. The recitals contained herein and in the Notes, except the Trustee’s certificate of authentication, shall be taken as the statements of the Company, and the Trustee assumes no responsibility for their correctness. The Trustee
makes no representations as to the validity or sufficiency of this Supplemental Indenture or of the Notes. The Trustee shall not be accountable for the use or application by the Company of the Notes or the proceeds thereof. 

Section 2.5 Governing Law. 
 This
Supplemental Indenture and the Notes shall be deemed to be a contract made under the internal laws of the State of New York, and for all purposes shall be construed in accordance with the laws of said State. 

  
 9 

 Section 2.6 Separability. 

In case any provision in this Supplemental Indenture shall for any reason be held to be invalid, illegal or unenforceable, the validity,
legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 
 Section 2.7 Counterparts. 

This Supplemental Indenture may be executed in any number of counterparts each of which shall be an original, but such counterparts shall
together constitute but one and the same instrument. 
 Section 2.8 No Benefit. 

Nothing in this Supplemental Indenture, express or implied, shall give to any Person other than the parties hereto and their successors or
assigns, and the Holders, any benefit or legal or equitable rights, remedy or claim under this Supplemental Indenture or the Base Indenture. 

  
 10 

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly
executed all as of the day and year first above written. 
  

			
	THERMO FISHER SCIENTIFIC INC.
		
	By:	 	 /s/ Anthony H. Smith

	Name:	 	Anthony H. Smith
	Title:	 	Vice President, Tax and Treasury and Treasurer

 [Nineteenth Supplemental Indenture] 

			
	THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee
		
	By:	 	/s/ Karen Yu
	Name:	 	Karen Yu
	Title:	 	Vice President

 [Nineteenth Supplemental Indenture] 

 EXHIBIT A 

[Insert the Global Security legend, if applicable] 

2.600% SENIOR NOTES DUE 2029 

 

 No. [        ]

 $[        ]

 

  
 CUSIP No. 883556 BZ4 

THERMO FISHER SCIENTIFIC INC. 
 promises
to pay to [                ] or registered assigns, the principal sum of
[                 ] Dollars on October 1, 2029. 
 Interest Payment
Dates: April 1 and October 1 
 Record Dates: March 17 and September 16 

Each holder of this Security (as defined below), by accepting the same, agrees to and shall be bound by the provisions hereof and of the
Indenture described herein, and authorizes and directs the Trustee described herein on such holder’s behalf to be bound by such provisions. Each holder of this Security hereby waives all notice of the acceptance of the provisions contained
herein and in the Indenture and waives reliance by such holder upon said provisions. 
 This Security shall not be entitled to any benefit
under the Indenture, or be valid or become obligatory for any purpose, until the Certificate of Authentication hereon shall have been signed by or on behalf of the Trustee. The provisions of this Security are continued on the reverse side hereof,
and such continued provisions shall for all purposes have the same effect as though fully set forth at this place. 

  
 A-1 

 IN WITNESS WHEREOF, the Company has caused this instrument to be signed in accordance with Section 2.04
of the Base Indenture. 
 Date: [                ] 

 

	
	THERMO FISHER SCIENTIFIC INC.
	
	   

	Name:
	Title:
	
	   

	Name:
	Title:

  
 A-2 

 CERTIFICATE OF AUTHENTICATION 

This is one of the 2.600% Senior Notes due 2029 issued by Thermo Fisher Scientific Inc. of the series designated therein referred to in the within-mentioned
Indenture. 
 Date: [                ] 

 

			
	 THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A.

      as Trustee

		
	By:	 	 
		 	Authorized Signatory

  
 A-3 

 Thermo Fisher Scientific Inc. 

2.600% Senior Notes due 2029 
 This
security is one of a duly authorized series of debt securities of Thermo Fisher Scientific Inc., a Delaware corporation (the “Company”), issued or to be issued in one or more series under and pursuant to an Indenture for the Company’s
unsubordinated debt securities, dated as of November 20, 2009 (the “Base Indenture”), duly executed and delivered by and between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (the “Trustee”), as
supplemented by the Nineteenth Supplemental Indenture, dated as of October 8, 2019 (the “Supplemental Indenture”), between the Company and the Trustee. The Base Indenture as supplemented and amended by the Supplemental Indenture is
referred to herein as the “Indenture.” By the terms of the Base Indenture, the debt securities issuable thereunder are issuable in series that may vary as to amount, date of maturity, rate of interest and in other respects as provided in
the Base Indenture. This security is one of the series designated on the face hereof (individually, a “Security,” and collectively, the “Securities”), and reference is hereby made to the Indenture for a description of the rights,
limitations of rights, obligations, duties and immunities of the Trustee, the Company and the holders of the Securities (the “Securityholders”). Capitalized terms used herein and not otherwise defined shall have the meanings given them in
the Base Indenture or the Supplemental Indenture, as applicable. 
 1. Interest. The Company promises to pay interest on the principal
amount of this Security at an annual rate of 2.600%. The Company will pay interest semi-annually on April 1 and October 1 of each year (each such day, an “Interest Payment Date”) until the principal is paid or made available for
payment. If any Interest Payment Date, Optional Redemption Date or maturity date of this Security is not a Business Day, the required payment of interest or principal (and premium, if any) shall be made on the next succeeding Business Day with the
same force and effect as if made on the date such payment was due, and no interest shall accrue on the amount so payable for the period from and after such date to the date of such payment on the next succeeding Business Day. Interest on the
Securities will accrue from the most recent date to which interest has been paid or duly made available for payment or, if no interest has been paid, from the date of issuance; provided that, if there is no existing Default in the payment of
interest, and if this Security is authenticated between a regular record date referred to on the face hereof and the next succeeding Interest Payment Date, interest shall accrue from such next succeeding Interest Payment Date; and provided,
further, that the first Interest Payment Date shall be April 1, 2020. Interest will be calculated on the basis of a 360-day year of twelve 30-day months. 

2. Method of Payment. The Company will pay interest on the Securities (except defaulted interest), if any, to the persons in whose name
such Securities are registered at the close of business on the regular record date referred to on the facing page of this Security for such interest installment. In the event that the Securities or a portion thereof are called for redemption
pursuant to an optional redemption or there is a Change of Control Offer, and the Optional Redemption Date or the Change of Control Payment Date, as applicable, is subsequent to a regular record date with respect to any Interest Payment Date and
prior to such Interest Payment Date, interest on such Securities shall instead be paid upon presentation and surrender of such Securities as provided in the Indenture. The principal of, and interest on, the Securities shall be payable in the coin or
currency of the United States of America that at the time is legal tender for public and private debt, at the office or agency of the Company maintained for that purpose in accordance with the Indenture. 

  
 A-4 

 3. Paying Agent and Registrar. Initially, The Bank of New York Mellon Trust Company,
N.A. shall act as paying agent and Security Registrar. Upon prior notice to the Trustee, the Company may change or appoint any paying agent or Security Registrar without notice to any Securityholder. The Company or any of its Subsidiaries may act in
any such capacity. 
 4. Indenture. The terms of the Securities include those stated in the Indenture and those made part of the
Indenture by reference to the Trust Indenture Act of 1939, as amended (“TIA”) as in effect on the date the Indenture is qualified. The Securities are subject to all such terms, and Securityholders are referred to the Indenture and TIA for
a statement of such terms. In the event of a conflict between the terms of the Securities and the terms of the Indenture, the terms of the Indenture shall prevail. The Securities are unsecured general obligations of the Company and constitute the
series designated on the face hereof as the “2.600% Senior Notes due 2029,” initially limited to $900,000,000 in aggregate principal amount. The Company shall furnish to any Securityholder upon written request and without charge a copy of
the Base Indenture and the Supplemental Indenture. Requests may be made to: Thermo Fisher Scientific Inc., 168 Third Avenue, Waltham, Massachusetts 02451, Attention: Michael A. Boxer. 

5. Redemption. The Securities may be redeemed at the option of the Company prior to the maturity date, as provided in Section 1.3
of the Supplemental Indenture. The Company shall not be required to make sinking fund payments with respect to the Securities. 
 6.
Change of Control Triggering Event. Upon the occurrence of a Change of Control Triggering Event, unless the Company has redeemed this Security or the Company has defeased this Security or satisfied and discharged this Security, the
Securityholder of this Security shall have the right to require that the Company purchase all or a portion (such principal amount to be equal to $2,000 or an integral multiple of $1,000 in excess thereof), of this Security at a purchase price equal
to 101% of the aggregate principal amount repurchased plus accrued and unpaid interest, if any, on the amount to be repurchased up to, but excluding, the date of purchase. Within 30 days following any Change of Control Triggering Event, the Company
shall deliver a notice to each Securityholder, in accordance with Section 1.4(a) of the Supplemental Indenture, with a copy to the Trustee, which notice shall govern the terms of the Change of Control Offer. 

7. Denominations, Transfer, Exchange. The Securities are in registered form without coupons in the denominations of $2,000 or an
integral multiple of $1,000 in excess thereof. The transfer of Securities may be registered and Securities may be exchanged as provided in the Indenture. The Securities may be presented for exchange or for registration of transfer (duly endorsed or
with the form of transfer endorsed thereon duly executed if so required by the Company or the Security Registrar) at the office of the Security Registrar or at the office of any transfer agent designated by the Company for such purpose. No service
charge shall be made for any registration of transfer or exchange, but a Securityholder may be required to pay any applicable taxes or other governmental charges. If the Securities are to be redeemed, the Company shall not be required to:
(i) issue, register the transfer of, or exchange any Security 

  
 A-5 

 
during a period beginning at the opening of business 15 days before the day of delivery of a notice of redemption of less than all of the outstanding Securities and ending at the close of
business on the day of such delivery; (ii) register the transfer of or exchange any Security or portions thereof selected for redemption, in whole or in part, except the unredeemed portions of any such Security being redeemed in part; nor
(iii) register the transfer of or exchange of a Security between the applicable record date and the next succeeding Interest Payment Date. 

8. Persons Deemed Owners. The registered Securityholder may be treated as its owner for all purposes. 

9. Repayment to the Company. Any funds or Governmental Obligations deposited with any paying agent or the Trustee, or then held by the
Company, in trust for payment of principal of, premium, if any, or interest on the Securities that are not applied but remain unclaimed by the holders of such Securities for at least one year after the date upon which the principal of, premium, if
any, or interest on such Securities shall have respectively become due and payable, shall be repaid to the Company, as applicable, or (if then held by the Company) shall be discharged from such trust. After return to the Company, Securityholders
entitled to the money or securities must look to the Company, as applicable, for payment as unsecured general creditors. 
 10.
Amendments, Supplements and Waivers. The Indenture permits, with certain exceptions as therein provided, the amendment thereof and the modification of the rights and obligations of the Company and the rights of the Securityholders of the
Securities to be affected under the Indenture at any time by the Company and the Trustee with the consent of the Securityholders of a majority in principal amount of the Securities at the time Outstanding to be affected. The Indenture also contains
provisions permitting the Securityholders of a majority in principal amount of the Securities at the time Outstanding, on behalf of the Securityholders of all Securities, to waive compliance by the Company with certain provisions of the Indenture
and certain past defaults under the Indenture and their consequences. Any such consent or waiver by the Securityholder of this Security shall be conclusive and binding upon such Securityholder and upon all future Securityholders of this Security and
of any Security issued upon the registration of transfer hereof or in exchange herefor or in lieu hereof, whether or not notation of such consent or waiver is made upon this Security. 

11. Defaults and Remedies. If an Event of Default with respect to the Securities occurs and is continuing, the Trustee or the
Securityholders of at least 25% in aggregate principal amount of the Securities then Outstanding, by notice in writing to the Company (and to the Trustee if notice is given by such Securityholders), may declare the entire principal of, premium, if
any, and accrued interest, if any, of such Securities due and payable immediately. Subject to the terms of the Indenture, if an Event of Default under the Indenture shall occur and be continuing, the Trustee shall be under no obligation to exercise
any of its rights or powers under the Indenture at the request or direction of any of the Securityholders, unless such Securityholders have offered the Trustee indemnity satisfactory to it. Upon satisfaction of certain conditions set forth in the
Indenture, the Securityholders of a majority in principal amount of the Outstanding Securities shall have the right to direct the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or
power conferred on the Trustee, with respect to the Securities. 

  
 A-6 

 12. Trustee, Paying Agent and Security Registrar May Hold Securities. The Trustee,
subject to certain limitations imposed by the TIA, or any paying agent or Security Registrar, in its individual or any other capacity, may become the owner or pledgee of Securities with the same rights it would have if it were not Trustee, paying
agent or Security Registrar. 
 13. No Recourse Against Others. No recourse under or upon any obligation, covenant or agreement of the
Indenture, or of any Security, or for any claim based thereon or otherwise in respect hereof or thereof, shall be had against any incorporator, stockholder, officer or director, past, present or future as such, of the Company or of any predecessor
or successor corporation, either directly or through the Company or any such predecessor or successor corporation, whether by virtue of any constitution, statute or rule of law, or by the enforcement of any assessment or penalty or otherwise; it
being expressly understood that the Indenture and the obligations issued hereunder and thereunder are solely corporate obligations, and that no such personal liability whatever shall attach to, or is or shall be incurred by, the incorporators,
stockholders, officers or directors as such, of the Company or of any predecessor or successor corporation, or any of them, because of the creation of the indebtedness authorized by the Indenture, or under or by reason of the obligations, covenants
or agreements contained in the Indenture or in the Securities or implied therefrom; and that any and all such personal liability of every name and nature, either at common law or in equity or by constitution or statute, of, and any and all such
rights and claims against, every such incorporator, stockholder, officer or director as such, because of the creation of the indebtedness authorized by the Indenture, or under or by reason of the obligations, covenants or agreements contained in the
Indenture or in the Securities or implied therefrom, are hereby expressly waived and released as a condition of, and as a consideration for, the acceptance of the Securities. 

14. Discharge of Indenture. The Indenture contains certain provisions pertaining to discharge and defeasance, which provisions shall for
all purposes have the same effect as if set forth herein. 
 15. Authentication. This Security shall not be valid until the Trustee
signs the certificate of authentication attached to the other side of this Security. 
 16. Additional Amounts. The Company is
obligated to pay Other Additional Amounts on this Security to the extent provided in Section 10.03 of the Base Indenture. 
 17.
Abbreviations. Customary abbreviations may be used in the name of a Securityholder or an assignee, such as: TEN COM (= tenants in common), TEN ENT (= tenants by the entireties), JT TEN (= joint tenants with right of survivorship and not as
tenants in common), CUST (= Custodian), and U/G/M/A (= Uniform Gifts to Minors Act). 
 18. Governing Law. The Base Indenture, the
Supplemental Indenture and this Security shall be deemed to be a contract made under the internal laws of the State of New York, and for all purposes shall be construed in accordance with the laws of said State. 

  
 A-7 

 ASSIGNMENT FORM 

To assign this Security, fill in the form below: (I) or (we) assign and transfer this Security to 

 
  

(Insert assignee’s soc. sec. or tax I.D. no.) 
  

 
  

 
  

 
  

 
 (Print or type assignee’s name,
address and zip code) 
 and irrevocably appoint
                                         
                                    agent to transfer this Security on
the books of the Company. The agent may substitute another to act for him. 
  

 
 Date:
                     
  

	
	Your Signature:                                   
                          
	(Sign exactly as your name appears on the face of this Security)

 Signature Guarantee:
                                        
     

  
 A-8 

 OPTION OF HOLDER TO ELECT PURCHASE 

If you want to elect to have this Security purchased by the Company pursuant to Section 1.4 of the Supplemental Indenture, check the box:

  

	☐	 1.4 Change of Control Triggering Event 

If you want to elect to have only part of this Security purchased by the Company pursuant to Section 1.4 of the Supplemental Indenture,
state the amount: $                . 
  

			
	Date:                                 	  	Your Signature:
		  	 (Sign exactly as your name appears
 on the other
side of the Security)

 Tax I.D. Number: 
  

	
	 Signature Guarantee:
                                         
                       

	  (Signature must be guaranteed by a

 participant in a recognized signature

 guarantee medallion program)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}]]